Current Review of Pneumoconiosis Among US Coal Miners

Hall, Noémi B.; Blackley, David J.; Halldin, Cara N.; Laney, A. Scott

doi:10.1007/s40572-019-00237-5

Cited by 82 publications

(57 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pneumoconiosis is a kind of lung disease caused by inhalation of dust, such as silica (commonly named siliconosis), coal and rock dust and is characterized by inflammation, coughing, and fibrosis 93 . Early pneumoconiosis may be asymptomatic, but advanced stages of pneumoconiosis result in airflow limitation, hypoxia, pulmonary hypertension, respiratory or heart failure, and premature death, even without further exposure to the dust 94 . Currently, there is no effective drug treatment.…”

Section: Resultsmentioning

confidence: 99%

Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review

Chen¹,

Wang

Huang

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Lung disorders are a leading cause of morbidity and death worldwide. For many disease conditions, no effective and curative treatment options are available. Mesenchymal stromal cell (MSC)-based therapy is one of the cutting-edge topics in medical research today. It offers a novel and promising therapeutic option for various acute and chronic lung diseases due to its potent and broad-ranging immunomodulatory activities, bacterial clearance, tissue regeneration, and proangiogenic and antifibrotic properties, which rely on both cell-to-cell contact and paracrine mechanisms. This review covers the sources and therapeutic potential of MSCs. In particular, a total of 110 MSC-based clinical applications, either completed clinical trials with safety and early efficacy results reported or ongoing worldwide clinical trials of pulmonary diseases, are systematically summarized following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, including acute/viral pulmonary disease, community-acquired pneumonia (CAP), chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia (BPD), interstitial lung diseases (ILD), chronic pulmonary fibrosis, bronchiolitis obliterans syndrome (BOS) and lung cancer. The results of recent clinical studies suggest that MSCs are a promising therapeutic approach for the treatment of lung diseases. Nevertheless, large-scale clinical trials and evaluation of long-term effects are necessary in further studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review

Chen¹,

Wang

Huang

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Figure 4 demonstrates the limited cab collection efficiency for nano-scale dusts as marked in red. Also, the protection factor (the average outside respirable dust concentration divided by the inside cab dust concentration) is high for the nano-scale dusts as measured by GRIMM Particle monitors (Gresh et al 1994). The potential second dust sources during loading and hauling of ''mucks'' can liberate existing dusts, which have been attached on the surface of broken rocks, via using LHD (load-haul-dump) vehicles and muckers.…”

Section: Potential Dust Sources For the Completed Mining Cyclementioning

confidence: 99%

“…A dramatic increase of the prevalence of progressive massive fibrosis among working underground coal miners in central Appalachia has been observed in the past decade although stringent regulations have been proposed by MSHA and NIOSH, as shown in Fig. 1 (Blackley et al 2018;Doney et al 2019;Hall et al 2019). The 2018 National Academic of Sciences (NAS) report about mine dust explosion indicted that changes in mining practices, conditions, and technologies during the past decades might have led the changes of the typical dust-size distribution of both silica and coal dusts, which could result in the changes of disease epidemiology (Coal et al 2018).…”

Section: Introductionmentioning

confidence: 99%

Respirable nano-particulate generations and their pathogenesis in mining workplaces: a review

Fan

Liu

2021

Int J Coal Sci Technol

View full text Add to dashboard Cite

There is a growing concern in mining community about the contribution of nano-particulates to miner’s health. Despite the health influence of respirable dusts and associated lung diseases have been recognized for decades in the mining industry, the nano-scale particulates accompanying with complicated physiochemical properties and their enormous contribution in quantity have been drawing attentions only in recent a few years because of the advancement of nano-science discipline. In this review, we examine the current regulations of dusts exposure and the dominant mass-based monitoring methods to point out the ignorance of nano-particulates in mining industry. The recognized mining-related nano-particulates sources are summarized to identify the mechanically generated finer particulates including particles and aerosols. In addition, the mechanism of adverse health impact on miner with exposure to nano-scale particulates is discussed in a detail to emphasize their substantial detriment as a potential respiratory hazard. Characterization of the complex physiochemical properties of nano-particulates are then summarized and discussed because these properties could be different from regular respirable dusts due to their dramatically increased surface area and particulate counts. The intent of this review is to demonstrate the potential of adverse health effect of nano-particulate on the mine personals throughout the mining cycle and to identify the research gaps of the mine nano-particulate characterization and quantification. We suggest that further understanding of the mining induced nano-particulate properties and their pathogenesis are critical for the future engineering control measure to mitigate the potential health threat for future miners.

show abstract

“…Cumulative inhalation of RCMD can lead to severe lung diseases, including coal worker's pneumoconiosis (CWP), silicosis, mixed dust pneumoconiosis, dust-related diffuse fibrosis (DDF), and progressive massive fibrosis (PMF) [27][28][29]. Black lung or CWP has been considered as a main concern among US coal workers since 1962 that followed by regulations to decrease the limits of dust exposure once in a while.…”

Section: Introductionmentioning

confidence: 99%

Respirable Coal Mine Dust: A Review of Respiratory Deposition, Regulations, and Characterization

et al. 2021

View full text Add to dashboard Cite

In the late 1990s, despite years of efforts to understand and reduce coal worker’s pneumoconiosis (CWP) prevalence from more than 30% in 1970 to less than 4.2%, the level of occurrence among the US coal miners increased unexpectedly. The recent resurgence of lung diseases has raised concerns in the scientific and regulatory communities. In 2014, the United States Mine Safety and Health Administration (MSHA) issued a new dust rule changing the respirable coal mine dust (RCMD) exposure limits, measurement technology, and sampling protocol. The analysis for probable causes for the substantial increase in the CWP incidence rate is rather complicated. This paper aims to conduct a review of RCMD respiratory deposition, health effects, monitoring, regulations, and particle characteristics. The primary sources of RCMD along with the health risks from potential exposure are highlighted, and the current RCMD exposure regulations of the major coal producer countries are compared. A summary of RCMD characterization studies from 1972 to the present is provided. A review of the literature revealed that numerous factors, including geological and mining parameters, advancements in mining practices, particle characteristics, and monitoring approaches are considered to contribute to the recent resurgence of RCMD lung diseases. However, the root causes of the problem are still unknown. The effectiveness of the new dust rules in the United States will probably take years to be correctly assessed. Therefore, future research is needed to understand the relationship between RCMD particle characteristics and lung deposition, and the efficacy of current monitoring practices to measure the true dose of RCMD exposure.

show abstract

Current Review of Pneumoconiosis Among US Coal Miners

Cited by 82 publications

References 54 publications

Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review

Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review

Respirable nano-particulate generations and their pathogenesis in mining workplaces: a review

Respirable Coal Mine Dust: A Review of Respiratory Deposition, Regulations, and Characterization

Contact Info

Product

Resources

About